Fri, Feb 27, 2015, 6:48 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • underdogs14 underdogs14 Jan 14, 2013 5:26 PM Flag

    Highlighting Will Lewis conference of 1/10/13

    Highlighting Cystic Fibrosis – No existing cure – patients taking 20 to 30 medications a day – Problem with medications now is growth of resistance to antibodies – Tobi is the leader in this space but they acknowledge 85% resistance growth – Tobi taken twice daily for 20 minutes each - The two leading drugs indicate downward trend line and lung function decline –

    Arikace – Taken once daily [inhaled] for 12 minutes – Chemically charged Liposomes [high efficiency drug encapsulation] gets absorbed and penetrates the mucus/biofilm layer of the lung and gets directly to the site of the infection where Amikacin [the encapsulated drug] gets delivered – Statistically significant and exciting data indicates [from their previous phase II extension study] that Arikace has a sustained benefit, even when the patient is NOT receiving drug – It is very unique in this feature.

    The phase III trial results coming mid 2013 head to head Arikace against Tobi – For European approval all that is needed is to demonstrate NON-INFERIORITY to Tobi drug. His comment about interest in Arikace.., this trial enrolled in 6 months when it took the other leaders 1 year to enroll before they receive approval

    Highlighting NTM – No approved treatment – More common than CF – Growing 8% per year – Over age 65 you are 40% more likely to die when diagnosed with NTM – Off label drugs treating this disease, none penetrate the lung.

    Arikace – Very good localized delivery to the lung – Delivers macrophage penetration – ‘Elite compound in this space’ – NTM is ‘ours to own’ – The phase II data’s primary endpoint is reduction of bacterial density by day 84 – Secondary endpoints as well – He believes with primary endpoint accomplishment, suitable for registration – potential for accelerated approval based on endpoint achievement, gain act, orphan and compassionate use launch after CF trial results – Will have dialogue with FDA as they met last September discussing endpoints .

    Insmed – Is preparing to launch based on both getting approved – 44 employees and growing – 2 year stability data from the manufacturer – Market exclusivity to 2029 but likely into the 3030’s

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
18.54+0.38(+2.09%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.